Fatty liver on computed tomography scan on admission is a risk factor for severe coronavirus disease
Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved..
OBJECTIVES: To alleviate the overflow of coronavirus disease 2019 (COVID-19) patients in hospitals, less invasive and simple criteria are required to triage the patients. We evaluated the relationship between COVID-19 severity and fatty liver on plain computed tomography (CT) scan performed on admission.
METHODS: In this retrospective cohort study, we considered all COVID-19 patients at a large tertiary care hospital between January 31 and August 31, 2020. COVID-19 severity was categorized into severe (moderate and severe) and non-severe (asymptomatic and mild) groups, based on the Japanese National COVID-19 guidelines. Fatty liver was detected on plain CT scan. Multivariate logistic regression analysis was performed to evaluate factors associated with severe COVID-19.
RESULTS: Of 222 patients (median age: 52 years), 3.2%, 58.1%, 20.7%, and 18.0% presented with asymptomatic, mild, moderate, and severe COVID-19, respectively. Although 59.9% had no fatty liver on plain CT, mild, moderate, and severe fatty liver occurred in 13.1%, 18.9%, and 8.1%, respectively. Age and presence of fatty liver were significantly associated with severe COVID-19.
CONCLUSION: Our study showed that fatty liver on plain CT scan on admission can become a risk factor for severe COVID-19. This finding may help clinicians to easily triage COVID-19 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy - 28(2022), 2 vom: 01. Feb., Seite 217-223 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Okuhama, Ayako [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 18.01.2022 Date Revised 18.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jiac.2021.10.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332945308 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332945308 | ||
| 003 | DE-627 | ||
| 005 | 20231225220623.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jiac.2021.10.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1109.xml |
| 035 | |a (DE-627)NLM332945308 | ||
| 035 | |a (NLM)34756574 | ||
| 035 | |a (PII)S1341-321X(21)00282-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Okuhama, Ayako |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fatty liver on computed tomography scan on admission is a risk factor for severe coronavirus disease |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.01.2022 | ||
| 500 | |a Date Revised 18.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a OBJECTIVES: To alleviate the overflow of coronavirus disease 2019 (COVID-19) patients in hospitals, less invasive and simple criteria are required to triage the patients. We evaluated the relationship between COVID-19 severity and fatty liver on plain computed tomography (CT) scan performed on admission | ||
| 520 | |a METHODS: In this retrospective cohort study, we considered all COVID-19 patients at a large tertiary care hospital between January 31 and August 31, 2020. COVID-19 severity was categorized into severe (moderate and severe) and non-severe (asymptomatic and mild) groups, based on the Japanese National COVID-19 guidelines. Fatty liver was detected on plain CT scan. Multivariate logistic regression analysis was performed to evaluate factors associated with severe COVID-19 | ||
| 520 | |a RESULTS: Of 222 patients (median age: 52 years), 3.2%, 58.1%, 20.7%, and 18.0% presented with asymptomatic, mild, moderate, and severe COVID-19, respectively. Although 59.9% had no fatty liver on plain CT, mild, moderate, and severe fatty liver occurred in 13.1%, 18.9%, and 8.1%, respectively. Age and presence of fatty liver were significantly associated with severe COVID-19 | ||
| 520 | |a CONCLUSION: Our study showed that fatty liver on plain CT scan on admission can become a risk factor for severe COVID-19. This finding may help clinicians to easily triage COVID-19 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Outcome | |
| 650 | 4 | |a Pneumonia | |
| 650 | 4 | |a Triage | |
| 700 | 1 | |a Hotta, Masatoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Ishikane, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kawashima, Akira |e verfasserin |4 aut | |
| 700 | 1 | |a Miyazato, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Terada, Mari |e verfasserin |4 aut | |
| 700 | 1 | |a Yamada, Gen |e verfasserin |4 aut | |
| 700 | 1 | |a Kanda, Kohei |e verfasserin |4 aut | |
| 700 | 1 | |a Inada, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Lubna |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Mitsuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Akiyama, Yutaro |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Tetsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamoto, Takato |e verfasserin |4 aut | |
| 700 | 1 | |a Nomoto, Hidetoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Ide, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Keiji |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Sho |e verfasserin |4 aut | |
| 700 | 1 | |a Kinoshita, Noriko |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Kei |e verfasserin |4 aut | |
| 700 | 1 | |a Morioka, Shinichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ujiie, Mugen |e verfasserin |4 aut | |
| 700 | 1 | |a Hayakawa, Kayoko |e verfasserin |4 aut | |
| 700 | 1 | |a Kustuna, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Shida, Yoshitaka |e verfasserin |4 aut | |
| 700 | 1 | |a Tajima, Tsuyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Teruya, Katsuji |e verfasserin |4 aut | |
| 700 | 1 | |a Funato, Yumi |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Makiko |e verfasserin |4 aut | |
| 700 | 1 | |a Izumi, Shinyu |e verfasserin |4 aut | |
| 700 | 1 | |a Hojo, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Sugiyama, Haruhito |e verfasserin |4 aut | |
| 700 | 1 | |a Ohmagari, Norio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |d 1996 |g 28(2022), 2 vom: 01. Feb., Seite 217-223 |w (DE-627)NLM095488073 |x 1437-7780 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:2 |g day:01 |g month:02 |g pages:217-223 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jiac.2021.10.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 2 |b 01 |c 02 |h 217-223 | ||